Aprepitant Suppliers & Bulk Manufacturers
Available Forms: Oral capsules, Injection (IV)
Available Strengths: Capsule (80 mg, 125 mg); Injection (IV):150 mg/3 mL
Reference Brands: Emend®(US & EU)
Category:
Oncology Cancer Care
Aprepitant 80 mg and 125 mg Capsules are essential in managing chemotherapy-induced nausea and vomiting (CINV). Available under the brand name Emend® in both oral capsule and intravenous injection (150 mg/3 mL) formulations, Aprepitant is a neurokinin-1 receptor antagonist used in combination with other antiemetic agents. Approved in both the U.S. and EU, it effectively prevents acute and delayed nausea and vomiting caused by chemotherapy treatments, particularly those with high emetogenic potential. Aprepitant plays a critical role in oncology B2B portfolios focused on supportive cancer care, improving patient quality of life during treatment.
Aprepitant is available in Oral capsules, Injection (IV)
and strengths such as Capsule (80 mg, 125 mg); Injection (IV):150 mg/3 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Aprepitant is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Aprepitant can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Aprepitant 80 mg and 125 mg Capsules are essential in managing chemotherapy-induced nausea and vomiting (CINV). Available under the brand name Emend® in both oral capsule and intravenous injection (150 mg/3 mL) formulations, Aprepitant is a neurokinin-1 receptor antagonist used in combination with other antiemetic agents. Approved in both the U.S. and EU, it effectively prevents acute and delayed nausea and vomiting caused by chemotherapy treatments, particularly those with high emetogenic potential. Aprepitant plays a critical role in oncology B2B portfolios focused on supportive cancer care, improving patient quality of life during treatment.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing